Top

Published in:

Open Access 01-12-2017 | REVIEW ARTICLE

The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles

Authors: Justyna Rosińska, Maria Łukasik, Wojciech Kozubski

Published in: Cardiovascular Drugs and Therapy | Issue 5-6/2017

Abstract

Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of activation. These microvesicles possess a wide range of properties, including prothrombotic, proatherogenic, proinflammatory, immunomodulatory, and even anticoagulant activity. The elevated release of these microvesicles has been observed in various metabolic, inflammatory, thrombotic, and vascular diseases, including ischemic heart disease, stroke, hypertension, diabetes, and connective tissue disease. Modulation of both pMV generation and the expression of their surface molecules may have beneficial clinical implications and could become a novel therapeutic target. However, mechanisms by which pharmacological agents can modify pMV formation are elusive. The purpose of this review is to discuss the effects of drugs routinely used in primary and secondary prevention of vascular disease on the release of pMV and expression of their surface procoagulant and proinflammatory molecules.

Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269–88.PubMedCrossRef

Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–46.PubMed

Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost. 2012;38:102–13.PubMedCrossRef

Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30:111–42.PubMedCrossRef

Lukasik M, Rozalski M, Luzak B, et al. Enhanced platelet-derived microparticle formation is associated with carotid atherosclerosis in convalescent stroke patients. Platelets. 2012;24:63–70.PubMedCrossRef

Cherian P, Hankey GJ, Eikelboom JW, et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke. 2003;34:2132–7.PubMedCrossRef

Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res. 1993;72:295–304.PubMedCrossRef

Shirafuji T, Hamaguchi H, Kanda F. Measurement of platelet-derived microparticle levels in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay. Kobe J Med Sci. 2008;54:55–61.

Bulut D, Becker V, Mügge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol. 2011;89:239–44.PubMedCrossRef

10.

George M, Ganesh MR, Sridhar A, et al. Evaluation of endothelial and platelet derived microparticles in patients with acute coronary syndrome. J Clin Diagn Res. 2015;9:OC09–13.PubMedPubMedCentral

11.

Michelsen AE, Brodin E, Brosstad F, Hansen JB. Increased level of platelet microparticles in survivors of myocardial infarction. Scand J Clin Lab Invest. 2008;68:386–92.PubMedCrossRef

12.

Preston RA, Jy W, Jiminez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41:211–7.PubMedCrossRef

13.

Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51:2840–5.PubMedCrossRef

14.

Murakami T, Horigome H, Tanaka K, et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res. 2007;119:45–53.PubMedCrossRef

15.

Stepanian A, Bourguignat L, Hennou S, et al. Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. Obesity. 2013;21:2236–43.PubMedCrossRef

16.

Kim HK, Song KS, Park YS, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184–91.PubMedCrossRef

17.

Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007;97:119–23.PubMed

18.

Zhang Y, Liu X, Liu L. Contact- and agonist-regulated microvesiculation of human platelets. Thromb Haemost. 2013;110:331–9.PubMedCrossRef

19.

França CN, Pinheiro LF, Izar MC, et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J. 2012;76:729–36.PubMedCrossRef

20.

Kafian S, Mobarrez F, Wallen H, Samad B. Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets. 2015;26:467–73.PubMedCrossRef

21.

Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol. 2000;121:437–43.PubMedPubMedCentralCrossRef

22.

Nomura S, Shouzu A, Omoto S, et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost. 1998;80:388–92.PubMed

23.

Omoto S, Nomura S, Shouzu A, et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron. 1999;81:271–7.PubMedCrossRef

24.

Chen Y, Xiao Y, Lin Z, et al. The role of circulating platelets microparticles and platelet parameters in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2015;24:2313–20.PubMedPubMedCentralCrossRef

25.

Goto S, Tamura N, Li M, et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost. 2003;1:2022–30.PubMedCrossRef

26.

Böing A, Valkonen S, Sturk A, Hajji N, Chi Hau, Nieuwland R. Platelet-derived extracellular vesicles exposing fibrinogen may be a potential marker for ongoing thrombus formation. The Fifth International Meeting of ISEV, ISEV2016 Rotterdam, The Netherlands, 4–7 May, 2016 Abstracts.

27.

Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost. 2004;2:1118–26.PubMedCrossRef

28.

Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol. 2004;43:162–8.PubMedCrossRef

29.

Šuštar V, Janša R, Frank M, et al. Suppression of membrane microvesiculation—a possible anticoagulant and anti-tumor progression effect of heparin. Bllod Cells Mol Dis. 2009;42:223–7.CrossRef

30.

Pawelczyk M, Chmielewski H, Kaczorowska B, Przybyła M, Baj Z. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci. 2015;11:115–21.PubMedPubMedCentralCrossRef

31.

Pinheiro LF, Franca CN, Izar MC, et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int J Cardiol. 2012;158:125–9.PubMedCrossRef

32.

Almquist T, Mobar F, Jacobson SH, Wallén H, Hjemdahl P. Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. 2016;31:944–52.PubMedCrossRef

33.

Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S. Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin Appl Thromb Hemost. 2001;7:153–7.PubMedCrossRef

34.

Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J. 2006;27:817–23.PubMedCrossRef

35.

Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009;20:16–22.PubMedCrossRef

36.

Del Turco S, Basta G, Lazzerini G, et al. Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica. 2008;93:892–9.PubMedCrossRef

37.

Nomura S, Kanazawa S, Fukuhara S. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with type 2 diabetes mellitus. J Diabetes Complicat. 2003;17:153–9.PubMedCrossRef

38.

Nomura S, Omoto S, Yokoi T, et al. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med. 2011;4:539–45.PubMedPubMedCentralCrossRef

39.

Okuda Y, Omoto S, Taniura T, Shouzu A, Nomura S. Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis. Int J Gen Med. 2016;9:65–71.PubMedPubMedCentral

40.

Shimazu T, Inami N, Satoh D, et al. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis. 2009;28:429–35.PubMedCrossRef

41.

Skeppholm M, Mobarrez F, Malmqvist K, Wallén H. Platelet-derived microparticles during and after acute coronary syndrome. Thromb Haemost. 2012;107:1122–9.PubMedCrossRef

42.

Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res. 2005;115:277–85.PubMedCrossRef

43.

Nomura S, Inami N, Kimura Y, et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens. 2007;21:38–44.PubMedCrossRef

44.

Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens. 2002;16:539–47.PubMedCrossRef

45.

Morel O, Luca F, Grunebaum L, et al. Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. Int J Obes. 2011;35:1479–86.CrossRef

46.

Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 1996;88:3456–64.PubMed

47.

Holme PA, Orvim U, Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 1997;17:646–53.PubMedCrossRef

48.

Bode AP, Knupp CL. Effect of cold storage on platelet glycoprotein Ib and vesiculation. Transfusion. 1994;34:690–6.PubMedCrossRef

49.

Gemmel CH, Sefton MV, Yeo E. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann’s thrombasthenia defect. J Biol Chem. 1993;268:14586–9.

50.

Van Wijk MJ, Van Bavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59:277–87.CrossRef

51.

Yano Y, Kambayashi J, Shiba E, et al. The role of protein phosphorylation and cytoskeletal reorganization in microparticle formation from the platelet plasma membrane. Biochem J. 1994;299:303–8.PubMedPubMedCentralCrossRef

52.

Distler JH, Huber LC, Hueber AJ, et al. The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis. 2005;10:731–41.PubMedCrossRef

53.

Cauwenberghs S, Feijge MA, Harper AG, Sage SO, Curvers J, Heemskerk JW. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. FEBS Lett. 2006;580:5313–20.PubMedCrossRef

54.

George JN, Pickett EB, Saucerman S, et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340–8.PubMedPubMedCentralCrossRef

55.

Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood. 2008;111:5028–36.PubMedPubMedCentralCrossRef

56.

Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988;263:18205–12.PubMed

57.

Milioli M, Ibanez-Vea M, Sidoli S, Palmisano G, Careri M, Larsen MR. Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists. J Proteome. 2015;121:56–66.CrossRef

58.

Boilard E, Duchez AC, Brisson A. The diversity of platelet microparticles. Curr Opin Hematol. 2015;22:437–44.PubMedCrossRef

59.

Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009;113:1112–21.PubMedPubMedCentralCrossRef

60.

Iwamoto S, Kawasaki T, Kambayashi J, Ariyoshi H, Monden M. Platelet microparticles: a carrier of platelet-activating factor? Biochem Biophys Res Commun. 1996;218:940–4.PubMedCrossRef

61.

Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998;80:171–5.PubMed

62.

Nomura S, Komiyama Y, Miyake T, et al. Amyloid-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost. 1994;72:519–22.PubMed

63.

Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 1991;77:2641–8.PubMed

64.

Barry OP, Practico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99:2118–27.PubMedPubMedCentralCrossRef

65.

Garcia B, Smalley DM, Cho H, Shabanowitz J, Ley K, Hunt DF. The platelet particle proteome. J Proteome Res. 2005;4:1516–21.PubMedCrossRef

66.

Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97:425–34.PubMed

67.

Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res. 2008;123:8–23.PubMedCrossRef

68.

Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991;266:17261–8.PubMed

69.

Hoffnan M, Monroe DM, Roberts HR. Coagulation factor IXa binding to activated platelets and platelet derived microparticles: a flow cytometric study. Thromb Haemost. 1992;68:74–8.

70.

Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004;104:3190–7.PubMedCrossRef

71.

Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension. 2004;43:428–33.PubMedCrossRef

72.

Barry OP, Practico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136–44.PubMedPubMedCentralCrossRef

73.

Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005;25:1512–8.PubMedCrossRef

74.

Forlow SB, McEver R, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood. 2000;95:1317–23.PubMed

75.

Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752–60.PubMedCrossRef

76.

Laffont B, Corduan A, Plé H, et al. Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood. 2013;122:253–61.PubMedCrossRef

77.

Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost. 2011;105:396–408.PubMedCrossRef

78.

Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F. Standardization of platelet-derived microparticle enumeration by flow cytometry using calibrated beads: results of ISTH SSC collaborative workshop. J Thromb Haemost. 2010;8:2571–2.PubMedCrossRef

79.

Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.PubMedCrossRef

80.

Barry OP, Kazanietz MG, Practico D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase c/mitogen-activated protein kinase-dependent pathway. J Biol Chem. 1999;274:7545–56.PubMedCrossRef

81.

Choudhury A, Chung I, Blann AD, Lip GY. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest. 2007;131:809–15.PubMedCrossRef

82.

Duarte RC, Gonçalves LH, Campos FM, et al. Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus. Blood Coagul Fibrinolysis. 2015;26:123–30.PubMedCrossRef

83.

Chiva-Blanch G, Suades R, Padro T, et al. Microparticle shedding by erythrocytes, monocytes and vascular smooth muscular cells is reduced by aspirin in diabetic patients. Rev Esp Cardiol. 2016;69:672–80.PubMedCrossRef

84.

Camargo LM, Franca CN, Izar MC, et al. Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. Braz J Med Biol Res. 2014;47:432–7.PubMedPubMedCentralCrossRef

85.

Combes V, Joly P, Ambrosi P, et al. Platelet vesiculation in angina patients treated with coronary angioplasty. Thromb Haemost. 2000;83:518.PubMed

86.

Mobarrez F, He S, Bröijersen A, et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost. 2011;106:344–52.PubMedCrossRef

87.

Lubsczyk B, Kollars M, Hron G, et al. Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur J Clin Investig. 2010;40:477–82.CrossRef

88.

Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepsis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75mg/day clopidogrel may be overcome within 1 month of treatment. Platelets. 2012;23:121–31.PubMedCrossRef

89.

Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost. 2010;103:1210–7.PubMedCrossRef

90.

Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925–34.PubMedCrossRef

91.

Kahner BN, Dorsam RT, Kunapuli SP. Role of P2Y receptor subtypes in platelet-derived microparticle generation. Front Biosci. 2008;13:433–9.PubMedCrossRef

92.

Jung WK, Lee DY, Park C, et al. Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol. 2010;159:1274–85.PubMedPubMedCentralCrossRef

93.

Nomura S, Inami N, Iwasaka T, Liu Y. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets. 2004;15:167–72.PubMedCrossRef

94.

Li H, Cone J, Fong M, Kambayashi J, Yoshitake M, Liu Y. Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation. Cardiovasc Drugs Ther. 2005;1:41–8.CrossRef

95.

Ichijo M, Ishibashi S, Ohkubo T, et al. Elevated platelet microparticle levels after acute ischemic stroke with concurrent idiopathic thrombocytopenic purpura. J Stroke Cerebrovasc Dis. 2014;23:587–9.PubMedCrossRef

96.

Wagner CL, Mascelli MA, Neblock DS. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907–14.PubMed

97.

Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost. 1994;72:1–15.PubMed

98.

Jeske WP, Walenga JM, Bakhos M. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res. 1997;88:271–81.PubMedCrossRef

99.

Matzdorf AC, Kuhnel G, Kemkes-Matthes B, Pralle H, Voss R, Farred J. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med. 2000;135:247–55.CrossRef

100.

Craft JA, Marsh NA. Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty. Blood Coagul Fibrinolysis. 2003;14:719–28.PubMedCrossRef

101.

Nagy B Jr, Szuk T, Debreceni IB, Kappelmayer J. Platelet-derived microparticle levels are significantly elevated in patients treated by elective stenting compared to subjects with diagnostic catheterization alone. Platelets. 2010;21:147–51.PubMedCrossRef

102.

Vargova K, Pállinger E, Horváth Z, et al. Drug-eluting stents promote late platelet-derived microvesicle release. Exp Clin Cardiol. 2014;20:3713–22.

103.

Tamburrelli C, Crescente M, Izzi B, et al. Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood. Thromb Res. 2011;128:446–51.PubMedCrossRef

104.

Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691–9.PubMed

105.

Otero R, Elias T, Montes-Worboys A, et al. Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis. Blood Coagul Fibrinolysis. 2011;22:628–9.PubMedCrossRef

106.

Amirkhosravi A, Mousa S, Amaya M, Francis J. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost. 2003;1:1972–6.PubMedCrossRef

107.

Pepke W, Eisenreich A, Jaster M, et al. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells. Cardiovasc Ther. 2013;31:115–23.PubMedCrossRef

108.

Holme PA, Brosstad F, Solum NO. Platelet-derived microvesicles and activated platelet express factor Xa activity. Blood Coagul Fibrinol. 1995;6:302–10.CrossRef

109.

Hérault B, Perrin C, Jongbloet AM, et al. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats. Thromb Haemost. 2000;84:668–74.PubMed

110.

Steppich B, Dobler F, Brendel LC, et al. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43:490–7.PubMedCrossRef

111.

Suades R, Padró T, Alonso R, Mata P, Badimon L. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost. 2013;110:366–77.PubMedCrossRef

112.

Tramontano AF, O’Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun. 2004;320:34–8.PubMedCrossRef

113.

Stach K, Nguyen XD, Lang S, et al. Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Cardiol J. 2012;19:20–8.PubMedCrossRef

114.

Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis. 2004;18:177–85.PubMedCrossRef

115.

Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194–9.PubMedCrossRef

116.

Tehrani S, Mobarrez F, Antovic A, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010;126:225–31.CrossRef

117.

Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost. 2005;3:1168–71.PubMedCrossRef

118.

Ali FY, Armstrong PC, Dhanji AR, et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol. 2009;29:706–11.PubMedCrossRef

119.

Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA. PPARbeta/delta agonists modulate platelet function via mechanism involving PPAR receptors and specific association/repression of PKC alpha—brief report. Arterioscler Thromb Vasc Biol. 2009;29:1871–3.PubMedCrossRef

120.

Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004;104:1361–8.PubMedCrossRef

121.

Chang TY, Chang C. Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metab. 2008;7:469–71.PubMedCrossRef

122.

Lins LC, França CN, Fonseca FA, et al. Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys. 2014;70:687–96.PubMedCrossRef

123.

Lijnen P, Echevaría-Vázquez D, Petrov V. Influence of cholesterol-lowering on plasma membrane lipids and function. Methods Find Exp Clin Pharmacol. 1996;18:123–36.PubMed

124.

Connolly KD, Willis GR, Datta Dev BN, et al. Lipoprotein apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia. J Lipid Res. 2014;55:2064–72.PubMedPubMedCentralCrossRef

125.

Nomura S, Suzuki M, Katsura K, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995;116:235–40.PubMedCrossRef

126.

Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today. 2013;49:615–29.PubMed

127.

Nomura S, Omoto S, Taniura T, Okuda Y, Shouzu. Combintion therapy of mitiglinide with alpha-glucosidase inhibitor and/or DPP-4I improves platelet-derived microparticle and adiponectin levels in patients with type 2 diabetes mellitus. J Endocrinol Diabetes. 2016;4:1081.

128.

Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther. 2009;329:669–76.PubMedCrossRef

129.

Esposito K, Ciotola M, Giugliano D. Pioglitazone reduces endothelial microparticles in the metabolic syndrome. Arterioslcer Thromb Vasc Biol. 2006;26:1926.CrossRef

130.

Tesse A, AL-Massarani G, Wangensteen R, Reitenbach S, Martınez MC. Andriantsitohaina rosiglitazone, a peroxisome proliferator-activated receptor-agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins. J Pharmacol Exp Ther. 2008;324:53–47.

131.

Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240–5.PubMedCrossRef

132.

Labiós M, Martínez M, Gabriel F, Guiral V, Ruiz Aja S, Aznar J. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens. 2004;17:757–63.PubMedCrossRef

133.

López Andrés N, Tesse A, Regnault V, et al. Increased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols. PLoS One. 2012;7:e39235.PubMedPubMedCentralCrossRef

134.

Phang M, Lincz L, Seldon M, Garg ML. Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects. J Nutr Biochem. 2012;23:1128–33.PubMedCrossRef

135.

Walz CP, Barry AR, Koshman SL. Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease. Can Pharm J. 2016;149:166–73.CrossRef

136.

Campello E, Zabeo E, Radu CM, et al. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thromb Haemost. 2015;113:85–96.PubMedCrossRef

137.

Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001;108:1533–40.PubMedPubMedCentralCrossRef

138.

Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999;48:426–9.PubMedCrossRef

139.

Lukasik M, Michalak S, Dworacki G, Kaczmarek M, Watala C, Kozubski W. Reactive leptin resistance and the profile of platelet activation in acute ischaemic stroke patients. Thromb Haemost. 2012;108:107–18.PubMedCrossRef

140.

Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T, Fukuhara S. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost. 2004;10:205–15.PubMedCrossRef

141.

Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost. 2006;4:1003–10.PubMedCrossRef

142.

Heinrich LF, Andersen DK, Cleasby ME, Lawson C. Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells. Br J Nutr. 2015;113:1704–11.PubMedCrossRef

143.

Rein D, Paglieroni TG, Wun T, et al. Cocoa inhibits platelet activation and function. Am J Clin Nutr. 2000;72:30–5.PubMed

144.

Schwartz V, Bachelier K, Schirmer SH, Werner C, Laufs U, Böhm M. Red wine prevents the acute negative vascular effects of smoking. Am J Med. 2017;130:95–100.CrossRef

145.

Mobarrez F, Antoniewicz L, Bosson JA, Kuhl J, Pisetsky DS, Lundbäck M. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One. 2014;9:e90314.PubMedPubMedCentralCrossRef

Title: The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles
Authors: Justyna Rosińska
Maria Łukasik
Wojciech Kozubski
Publication date: 01-12-2017
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 5-6/2017
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-017-6757-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2017

Find and Plug the Leak: Improving Adherence to Anti-Hypertensive Medicines

Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets

Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications

A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier

Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review

Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page